M V Chandrakanth/LinkedIn

Sep 29, 2026, 03:09

M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?

M V Chandrakanth, Academic Head and Medical Oncologist at Narayana Health, shared a post on LinkedIn:

“Aspirin in CRC – Old Drug, New Precision Oncology?

ALASCCA | 4-part quick revision

Part 1 – Why Aspirin?

The biology: PI3K–COX/PGE2 signaling and platelet-mediated metastatic escape as proposed mechanisms.

Part 2 – Who Got Aspirin?

Resected localized CRC and PI3K-pathway alteration – aspirin 160 mg/day vs placebo × 3 years.

Part 3 – Did it Work?

Primary Group A: 3-year recurrence 14.1% – 7.7% | HR 0.49.

Benefit also seen in the broader PI3K-altered Group B; absolute benefit was greater in higher-risk disease.

Part 4 – What Does It Men?

A compelling example of biomarker-directed drug repurposing – but OS benefit is not yet proven, and subgroup signals require caution.

Take-home:

Not aspirin for every CRC – aspirin for the right biology.”

M V Chandrakanth

M V Chandrakanth

'

Managing Thrombotic Risk in Pregnancy

'

10 Posts Not to Miss This Week

'

Targeted Thrombolysis Beyond tPA

'

10 Posts Not to Miss This Week

'

Hemostasis Today